Transgene SA · EURONEXT:TNG
Transgene SA — Investor Presentation (December 2005)
14 slides from Transgene SA's investor presentation, December 2005
Slide 1: Transgene Corporate Presentation December 2005
transgene TRANSGENE CORPORATE PRESENTATION December 2005
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements, including statements regarding Transgene’s objectives for progress in its clinical trials and product candidate development. Statements that are not historical facts are based on the Company's current expectations, beli
Slide 3: Key Dates
Key Dates § 1979 Foundation § 1979 Contract-research organization § 1992 Focus on gene transfer technology and product development § 1995 Completion of manufacturing facility (cGMP) § 2001 Focus on cancer immunotherapy § 2005 Broad pipeline of Phase I & II therapeutic vaccines in cancer and infectio
Slide 4: Financial History
Financial History IPO: : 1998 Paris Eurolist (FR 000 517 5080) and Nasdaq (TRGNY) Net proceeds of € 94 M Follow on: : 2001: Net proceeds of € 63 M; 2005: Net proceeds of € 32.6 M Public 41,80% Mérieux Group Shareholders: 56,70% French Muscular Dystrophy Association 1,50% Financials: Market capitaliz
Slide 5: A company focused on therapeutic vaccines against cancer and infectious diseases
A company focused on therapeutic vaccines against cancer and infectious diseases § Therapeutic vaccines: - a new class of therapeutics emerging after the monoclonal antibodies - synergistic with all other current treatment modalities § Cancer market: $20 bn, growing 15% per annum § Huge needs, unmet
Slide 6: Short term priorities
Short term priorities § Focus resources and capabilities towards achieving clinical proof of concept on most promising products and indications. § Out-license end of Phase II products through strategic alliances § Re-deploy research program beyond viral vectors § Leverage internal technology platfor
Slide 7: Substantial Pipeline, at key turning point
Substantial Pipeline, at key turning point Product Indication Preclinical Phase I Phase II Next phase TG4010 (MVA-MUC1-IL2) Lung cancer Phase IIb TG4001 (MVA-HPV-IL2) Prevention of Cervical cancer Phase II TG1042 (Ad-IFNγ) Cutaneous Lymphoma Phase II / III TG4040 (MVA-HCV) Hepatitis C Phase I / II M
Slide 8: TG 4010 (MVA-Muc1-IL2) therapeutic vaccine
TG 4010 (MVA-Muc1-IL2) therapeutic vaccine Market potential § MUC1 is a well described gene in literature, it § Lung cancer. First line treatment in combination with chemotherapy. is overexpressed in most of epihelial cells Estimated mortality EU/US 350,000 cancers (60% in non-small cell lung cancer
Slide 9: TG 4010 (MVA-Muc1-IL2) therapeutic vaccine
TG 4010 (MVA-Muc1-IL2) therapeutic vaccine TG4010: Phase II results (ASCO, May 2005) § PROSTATE CANCER 40 evaluable patients with rising PSA after primary treatment - 63 % had a significant increase in the time the PSA takes to double; - In 30% of the patients, the PSA doubling-time was more than tw
Slide 10: TG 4001 (MVA-HPV-IL2) therapeutic vaccine for the prevention of Cervical Cancer
TG 4001 (MVA-HPV-IL2) therapeutic vaccine for the prevention of Cervical Cancer Potential market § Infection by the Human Papilloma Virus (HPV) is § Prevention of cervical cancer. responsible for the development of precancerous Treatment of patients with precancerous cervical abnormality « cervical
Slide 11: TG 1042 (Ad-IFNγ) an immunotherapeutic product
TG 1042 (Ad-IFNγ) an immunotherapeutic product Potential market § Immunotherapy product developed for « Cutaneous § Cutaneous T-Cell Lymphoma. Orphan T- Cell Lymphoma» or « CTCL », a type of skin indication. Prevalence of 40 000 patients cancer EU/US. Potential sales estimated at about § Broad-spect
Slide 12: Other Projects
Other Projects § TG 4040 (MVA-HCV) ü A therapeutic vaccine against chronic hepatitis C infection ü Start of Phase I/II in H1 2006 § Myodys® ü Gene therapy against Duchenne Muscular Dystrophy ü Fully financed by the French Association Against Muscular Dystrophy ü Phase I/II planned in 2007 12 transge
Slide 13: Strong news flow offers many rebound opportunities in the next 12 months
Strong news flow offers many rebound opportunities in the next 12 months July 21, 2005: Merck & Co., Inc. achieves clinical milestone using Transgene’s proprietary technology October 13, 2005 : Transgene to manufacture HBV therapeutic vaccine for Innogenetics Q4 2005 H1 2006 H2 2006 Phase I/II TG104
Slide 14: Transgene Contacts
transgene Contacts Transgene Philippe Archinard, CEO Philippe Poncet, CFO +33 3 88 27 91 00 Transgene 67082 Strasbourg Cedex Web Site: www.transgene.fr